A Study to Create a Diagnostic Test for Patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure

Overview

Información sobre este estudio

The purpose of this study is to develop a diagnostic test using tissue biomarkers to provide an accurate diagnosis of alpha-synucleinopathies in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguishing between neurodegenerative diseases.

 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria - Synucleinopathy Subjects:

  • Men and women, age 40 to 99 years.
  • Willing to undergo a screening evaluation that includes a thorough medical history, physical and neurologic examination.
  • Clinically established diagnosis of Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies, pure autonomic failure, or a subject considered a healthy control at enrollment.
    • No subjects where the clinician is uncertain of the diagnosis should be enrolled in this study.
  • Diagnosis of Parkinson’s disease by UKPDS Brain Bank Criteria (Hughes 1992).
  • Diagnosis of multiple system atrophy by the Gilman Criteria (Gilman 2008).
  • Diagnosis of dementia with Lewy bodies by the 4th consensus on DLB consortium criteria (McKeith 2017).
  • Diagnosis of pure autonomic failure by chronic orthostatic hypotension (> 1 year) with a fall in systolic blood pressure > 30 mmHg from supine to standing position within 3 minutes.
  • Either absent phase 4 on Valsalva maneuver or at least 1 additional organ system involved (bowel, bladder).

Inclusion Criteria - Healthy Subjects:

  • Men and women, age 40 to 99 years.
  • Willing to undergo a screening evaluation that includes a thorough medical history, physical and neurologic examination.
  • Healthy subject with no history of clinical exam or symptoms suggestive of synucleinopathy.

Exclusion Criteria:

  • Subjects with evidence of RBD by history or questionnaire.
  • Individuals with a history or exam finding suggestive of anosmia, urinary dysfunction or chronic constipation.

 

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Wolfgang Singer, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20520701

Mayo Clinic Footer